Navigation Links
Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement
Date:4/20/2008

NEW YORK and WINNERSH, England, April 21 /PRNewswire/ -- Paul Capital Healthcare and Vernalis plc (LSE: VER) today announced that they have signed a financing agreement relating to frovatriptan, Vernalis' product for the treatment of migraine. Under the agreement, Vernalis will receive approximately euro 18.4 million in cash from Paul Capital Healthcare and, in return, Paul Capital Healthcare will receive approximately 90 per cent of Menarini's payments to Vernalis under their exclusive license and supply agreement for the commercialization of frovatriptan in Europe and certain other territories. Vernalis will continue to supply Menarini with frovatriptan active pharmaceutical ingredient.

Frovatriptan is currently approved for the acute treatment of migraine in Europe, the United States, Canada and seven Central American countries.

"Earlier this year, Vernalis restructured its operations to focus on its innovative discovery programs and to advance its promising pipeline of development stage products to the point at which they can be partnered. This transaction with Paul Capital Healthcare secures significant, non-dilutive funds for Vernalis, giving us the platform to rebuild new shareholder value in the medium term," said Tony Weir, CFO, Vernalis.

Dr. Ken Macleod, a partner at Paul Capital Healthcare, said: "Migraine affects about 10 percent of people and leads to billions of dollars in lost productivity each year. After extensively evaluating both the clinical and commercial data for frovatriptan, we believe this drug is positioned to capture a growing share of the market for migraine therapies. Growth capital is the hallmark of the companies and products in which Paul Capital Healthcare invests, and provides a compelling rationale for adding our investment in Vernalis and frovatriptan to our portfolio of investments."

About Paul Capital Partners and Paul Capital Healthcare

Through its funds, Paul Capital Healthcare is one
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPO Medical Retains American Capital Ventures for Investor Relations Services
2. MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting
3. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
4. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
7. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
8. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
9. Pharmasset Receives $10 Million of Working Capital
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Dana-Farber ... Cancer Science and Resolution Bioscience, Inc. today announced ... co-develop a novel, blood-based, clinic ready, Next Generation ... (NSCLC). The collaboration is the first to demonstrate ... and ROS1 fusions in blinded plasma samples and ...
(Date:4/16/2015)... CCI Global Channel Management, the world’s leading provider ... for major tech and telecom vendors, has released the ... vendor programs in software, hardware, and telecommunications industries. , ... top IT vendors in each segment focus their channel ... Assessment of the state of channel marketing ...
Breaking Biology Technology:Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3
... Chris Echeverri, Christoph Sachse, , ... GmbH , David ... RNA interference (RNAi) has become a powerful , ... wherein short double-stranded RNAs called short interfering , ...
... The first step in preparing a plasmid for siRNA , ... , that are susceptible to siRNA-induced degradation. ... more than half of the siRNAs provide at least a 50% , ... provide a 75-95% reduction. The general process ...
... Mammalian whole blood is a widely used tissue ... assays due to abundant genetic information as , ... isolation from whole blood is challenging, but Ambions ... RNA Isolation Kit uses strong denaturing , ...
Cached Biology Technology:siRNA Design: It's All in the Algorithm 2siRNA Design: It's All in the Algorithm 3siRNA Design: It's All in the Algorithm 4siRNA Design: It's All in the Algorithm 5siRNA Design: It's All in the Algorithm 6siRNA Design: It's All in the Algorithm 7siRNA Design: It's All in the Algorithm 8siRNA Design: It's All in the Algorithm 9siRNA Design: It's All in the Algorithm 10Selecting siRNA Sequences to Incorporate into the pSilencer Vectors 2Selecting siRNA Sequences to Incorporate into the pSilencer Vectors 3Selecting siRNA Sequences to Incorporate into the pSilencer Vectors 4Robust High Throughput RNA Isolation from Blood Samples 2Robust High Throughput RNA Isolation from Blood Samples 3Robust High Throughput RNA Isolation from Blood Samples 4
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
(Date:3/12/2015)... 12, 2015 IriTech, a leading iris based ... the Texas Instruments Design Network, announced today that the ... its IriShield USB MK2120U device during a launching event ... distribution. The iris scanner is manufactured ... in India through its Indian ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... interaction of negatively charged lipids and DNA molecules have ... delivery systems that will assist doctors and clinicians in ... As reported in the Aug. 9 issue of the ... now performed a careful, comprehensive study to see how ...
... latest version of the hide-and-seek game between pathogens and the ... to cloak itself with a recently discovered gene silencing device ... report by Howard Hughes Medical Institute (HHMI) researchers in an ... may be the first to show how a virus uses ...
... signaling pathway required for plants to grow to their normal ... the plant from wallpapering itself with too many densely clustered ... key to plants being able to survive on dry land ... University of Washington research associate in biology. She's one co-author ...
Cached Biology News:'Cookbook recipes' would cure disease with nontoxic DNA delivery systems 2Virus uses tiny RNA to evade the immune system 2Virus uses tiny RNA to evade the immune system 3Trio of plant genes prevent 'too many mouths' 2
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
...
Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
Biology Products: